Namenda

E494105

Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.

Try in SPARQL Jump to: Statements Referenced by

Statements (47)

Predicate Object
instanceOf brand name medication
pharmaceutical drug
affects N-methyl-D-aspartate receptors
approvalBy U.S. Food and Drug Administration NERFINISHED
availableAs oral solution
oral tablet
blackBoxWarning false
brandOwnerRegion United States NERFINISHED
canBeAdministeredWithFood true
chemicalSubClass adamantane derivative
commonSideEffect confusion
constipation
dizziness
headache
hypertension
contraindication known hypersensitivity to memantine
developedBy Allergan NERFINISHED
Forest Laboratories NERFINISHED
dosageForm immediate-release
eliminationRoute renal
FDAApprovalYear 2003
halfLife about 60–80 hours
hasActiveIngredient memantine hydrochloride
hasATCCode N06DX01
hasExtendedReleaseBrand Namenda XR NERFINISHED
hasGenericName memantine
indication moderate Alzheimer's disease
severe Alzheimer's disease
isNotDiseaseModifying true
legalStatusEU prescription only
legalStatusUS Rx-only
mayBeUsedWith cholinesterase inhibitors
metabolism minimal hepatic metabolism
pharmacologicalClass NMDA receptor antagonist
pregnancyCategoryUS Category B
prescriptionStatus prescription only
regulates excitatory neurotransmission
glutamate activity in the brain
requiresCautionIn severe renal impairment
routeOfAdministration oral
symptomaticTreatment true
targetPopulation patients with moderate to severe Alzheimer's dementia
therapeuticClass anti-dementia drug
treats Alzheimer's disease NERFINISHED
usedFor cognitive symptoms of Alzheimer's disease
functional symptoms of Alzheimer's disease
usedIn adult patients

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

memantine isMarketedUnderBrandName Namenda
subject surface form: Memantine